Collaborative Neuroscience Research LLC

1. Eli Lilly and Company $14,066,721 44 payments
2. Amgen Inc. $10,155,589 4 payments
3. Pfizer Inc. $4,881,193 182 payments
4. Teva Pharmaceuticals USA, Inc. $2,556,214 177 payments
5. Sumitomo Pharma America, Inc. $2,549,948 234 payments
6. AbbVie, Inc. $2,213,255 70 payments
7. Deciphera Pharmaceuticals Inc. $1,986,149 28 payments
8. H. Lundbeck A S $1,894,096 52 payments
9. Horizon Therapeutics plc $797,198 1 payment
10. Boehringer Ingelheim Pharmaceuticals, Inc. $753,766 20 payments

1. A Multiple-Dose Study to Investigate the Bioequivalence of Orforglipron (Ly3502970) Capsules and Orforglipron Tablets in Participants With Obesity Or Overweight Who Are Otherwise Healthy. $6,377,153 2 payments
2. A Multiple-Ascending Dose Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Ly3537031 in Overweight and Obese Participants and Healthy Volunteers $4,754,261 2 payments
3. A Phase 1, Randomized, Open-label, Parallel-group, Drug-drug Interaction Study to Evaluate the Effect of Antiemetic Medication on the Pharmacokinetics of AMG 133 in Participants Living With Overweight or Obesity $4,441,906 1 payment
4. A Phase 123 Placebocontrolled Randomized Observerblind Dosefinding Study to Evaluate the Safety Tolerability Immunogenicity and Efficacy of Sarscov2 Rna Vaccine Candidates Against Covid19 in Healthy Adults $3,327,794 86 payments
5. AMG 133 Titration PK Tolerability $2,363,322 1 payment
6. A Phase 1, Open label, Randomized, Single Dose Crossover Study to Assess the Relative Bioavailability of Olpasiran (AMG 890) Autoinjector and Prefilled Syringe in Healthy Participants $2,069,957 1 payment
7. A Phase 1 Study to Evaluate the Pharmacokinetics of Dcc-3014 in Healthy Adult Participants $1,986,149 28 payments
8. A Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, PK and PD of Ly4006895 in Healthy Volunteers and Patients With Early Symptomatic Ad $1,782,717 2 payments
9. A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study with an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients with Schizophrenia $1,305,113 59 payments
10. A Phase 1, Randomized, Double-blind, Multiple-dose Study to Evaluate the Pharmacokinetics of AMG 133 Administered Subcutaneously in Subjects With Overweight or Obesity $1,280,403 1 payment

1. Patient care $31,219 10 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.